Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681143 | 0.85 | PDE2A (0.34) | PDE2AEPHX2POLBL3MBTL1ALOX5AP | |
| SCHEMBL23389167 | 0.84 | PDE2A (0.41) | PDE2AEPHX2L3MBTL1IDO1SLC7A5 | |
| SCHEMBL30068477 | 0.84 | PDE2A (0.41) | PDE2AEPHX2L3MBTL1IDO1SLC7A5 | |
| SCHEMBL29453105 | 0.82 | EPHX2 (0.40) | PDE2AEPHX2SLC7A5 | |
| SCHEMBL22206764 | 0.82 | EPHX2 (0.40) | PDE2AEPHX2SLC7A5 | |
| SCHEMBL10333792 | 0.82 | PDE2A (0.40) | PDE2AEPHX2L3MBTL1IDO1SLC7A5 | |
| SCHEMBL30695929 | 0.82 | PDE2A (0.40) | PDE2AEPHX2L3MBTL1IDO1SLC7A5 | |
| SCHEMBL2650312 | 0.80 | L3MBTL1 (0.42) | POLBL3MBTL1MEN1APAF1ALDH1A1 | |
| SCHEMBL19411031 | 0.78 | POLB (0.50) | POLBL3MBTL1MEN1ALDH1A1MAPT | |
| SCHEMBL30038728 | 0.78 | POLB (0.50) | POLBL3MBTL1MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040911-B | As NAV1.8 2, 3-Dihydro-quinazoline Compounds as inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11702387-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702387-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702387-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| CN-110753682-B | Substituted indoline derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-110691773-B | Substituted indoline derivatives as dengue virus replication inhibitors | 杨森制药公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| CN-110461831-B | Substituted indoline derivatives as inhibitors of dengue virus replication | 杨森制药公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220340522-A1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2022-10-27 | — | — | US | disclosed |
| EP-3630723-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2022-08-24 | — | — | EP | disclosed |
| US-11407715-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2022-08-09 | — | — | US | disclosed |
| EP-3990436-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2022-05-04 | — | — | EP | disclosed |
| CN-114040911-A | As NAV1.8 inhibitors of 2, 3-dihydroquinazoline compounds | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3601266-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| EP-3630724-B1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020261114-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020035466-A1 | NOVEL SULFONEUREA COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795149-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | PDE2A 1324/4885EPHX2 2510/4885POLB 1025/4885 |
| US-20230103791-A1 | 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN1A, SCN1B | PDE2A 908/4885EPHX2 3208/4885POLB 4471/4885 |
| US-20220340522-A1 | SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | IDO1, INMT, IRF3 | PDE2A 1324/4885EPHX2 2510/4885POLB 1025/4885 |
| US-11407715-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | PDE2A 1324/4885EPHX2 2510/4885POLB 1025/4885 |
| US-11702387-B2 | Substituted indoline derivatives as dengue viral replication inhibitors | IDO1, INMT, IRF3 | PDE2A 1324/4885EPHX2 2510/4885POLB 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.